Tag Archives: Tuberculosis

Recent update on TB diagnostic techniques – GenXpert MTB/RIF Ultra

Posted on April 9, 2018 by

Guest posting: Dr Ian Marr, Microbiology Registrar, Pathology NSW, Hunter The GenXpert used in most LMIC has cartridges for detection of Mycobacterium tuberculosis (MTB) – GenXpert MTB/RIF. These contain primers and molecular beacon probes for the detection of both MTB … Continue reading →

Posted in Module- Mycobacteria | Tagged , | Leave a comment

Tuberculosis- drug resistant- online learning, mailing lists and references

Posted on December 8, 2016 by

Courtesy of Dr Suman Majumdar, Dr Catherine Berry and others. Therapeutics Recent presentation from our advanced trainee registrar concerning the new TB drugs: Brian_Chong 2017 New TB drugs. TB drug monographs :  up-to-date clinical profiles of TB drugs including guidance on … Continue reading →

Posted in Infectious diseases, Module- Mycobacteria, Mycobacteria tuberculosis | Tagged | Leave a comment

Excellent new Lancet series of tuberculosis papers

Posted on December 24, 2015 by

See this recent Lancet edition.  Article list below. Editorial comment Richard Horton et al (excerpt) : This latest Lancet Series is led by Salmaan Keshavjee, from Harvard Medical School’s Department of Global Health and Social Medicine. He helped bring together … Continue reading →

Posted in Journal | Tagged | Leave a comment

Antimicrobial resistance: WHY it matters, HOW did it arise and WHAT can we do about it – PNG focus

Posted on September 7, 2015 by

Global status of AMR with focus on PNG Medical Symposium Sept 2015 Why does AMR matter? Antimicrobial resistance kills- mortality higher for resistant pathogens AMR hampers the control of infectious diseases – prolonged infectivity – eg. MDR-TB AMR increases the … Continue reading →

Posted in A/m resistance, A/m stewardship, Infection prev & control, PNG | Tagged , | Leave a comment

Tuberculosis infection control – an essential priority

Posted on March 8, 2015 by

Control of healthcare TB transmission is an essential element of practice – protecting staff and other patients is paramount. Patients receiving drug therapy for drug susceptible TB are at increased risk for acquisition of MDR or XDR TB. WHO policy on … Continue reading →

Posted in Bacteria (GPOS), Module- Mycobacteria, Tuberculosis infection control | Tagged | Leave a comment